Comparing Ribociclib versus Palbociclib as a Second Line Treatment in Combination with Fulvestrant in Metastatic Breast Cancer: A Randomised Clinical Trial
Key Points
Key points are not available for this paper at this time.
Abstract
Assessment of CBR, PFS, QOL and toxicity profile of palbociclib and ribociclib.
Comparing Ribociclib versus Palbociclib as a Second Line Treatment in Combination with Fulvestrant in Metastatic Breast Cancer: A Randomised Clinical Trial | Synapse